Anastrozole Tablet
Product Images NDC 51991-620

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 51991-620). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Breckenridge Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Anastrozole 01

Chemical structure of Anastrozole showing its molecular arrangement with aromatic rings, nitrogen-containing heterocycles, and cyano and methyl groups.*

FDA Label Image

Anastrozole 02

A line graph depicting disease-free survival over time (in months) for patients treated with anastrozole versus tamoxifen. The y-axis shows the proportion alive and disease-free, while the x-axis indicates disease-free survival in months up to 90 months. Two lines represent the treatments: a dashed line for anastrozole and a solid line for tamoxifen. Below the graph, a table lists the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Anastrozole 03

A Kaplan-Meier curve chart showing disease-free survival over time in months for patients treated with anastrozole versus tamoxifen. The y-axis represents the proportion of patients alive and disease-free, while the x-axis shows disease-free survival time in months. The chart includes a risk table with patient counts at various time points for both treatment groups.*

FDA Label Image

Anastrozole 04

Kaplan-Meier survival curve showing the proportion of patients event-free over time in months comparing Anastrozole and Tamoxifen treatment groups. The chart includes the number of patients at risk at various time points up to 120 months. The vertical axis represents the proportion event free, and the horizontal axis shows time to event in months.*

FDA Label Image

Anastrozole 05

A Kaplan-Meier curve graph comparing the proportion event free over time (in months) for two randomized treatments: Anastrozole and Tamoxifen. The graph shows decreasing survival probabilities over 120 months, with Anastrozole represented by a solid line and Tamoxifen by a dashed line. Below the graph, a table lists the number of patients at risk at 12-month intervals for each treatment group.*

FDA Label Image

Anastrozole 06

A Kaplan-Meier plot comparing time to progression between Anastrozole and Tamoxifen treatments, showing the proportion of patients not progressing over time in months. The solid line represents Anastrozole, and the dashed line represents Tamoxifen. The chart includes patient counts at risk below the x-axis across various time points up to 32 months.*

FDA Label Image

Anastrozole 07

This line chart compares the proportion of patients not progressing over time in months, between randomized treatments of Anastrozole and Tamoxifen. The x-axis represents time to progression in months (0 to 42), and the y-axis represents the proportion not progressing (0 to 1.0). A table below shows the number of patients at risk at each time point for both treatments.*

FDA Label Image

Anastrozole 08

Packaging label for ANASTROZOLE tablets USP, 1 mg strength, provided as 30 tablets per bottle. The label lists the NDC as 51991-620-33 and states the drug is distributed by Breckenridge Pharmaceutical, Inc. and manufactured by Natco Pharma Limited, India. It includes dosage warning, storage instructions, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.